Monitor for upcoming earnings, clinical trial updates, or potential downgrades; coordinated C-suite selling may signal lack of confidence ahead of negative news. Watch for follow-up filings or increased trading volume.
ORKA drugs
ORKA drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 16 $41.75entry
- T+1 · 8mo ago −1.05%α −1.33% · $41.31
- T+5 · 8mo ago −0.46%α +1.59% · $41.56
- T+20 · 7mo ago +60.62%α +56.84% · $67.06
- T+60 · 5mo ago +53.44%α +42.95% · $64.06
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Multiple Oruka Therapeutics executives, including the CEO, CMO, and COO, sold shares in a coordinated cluster over a single day, totaling $248.8K in open-market sales. The CMO also exercised derivative securities, though most of those transactions were non-cash. The total value represents a small fraction of the company's $2.1B market cap.
Key Financial Metrics
Key Facts
- CEO Klein Lawrence Otto sold $71,407.7 worth of shares in an open-market transaction.
- CMO Goncalves Joana sold $117,158.68 of stock and exercised derivative securities (total nominal value $23,940, remainder non-cash).
- COO Sandler Laura Lee sold $24,780 in shares; CFO Agarwal Arjun sold $16,313.5.
- All transactions occurred on 2026-03-16, indicating a coordinated timing event.
- Total open-market sales by insiders: $248,732.78 across four executives.
Financial Impact
$248.7K in net insider selling over one day
Risk Factors
- Insider selling could precede negative clinical or financial news.
- Perception risk: multiple senior executives exiting positions may spook retail investors.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (8 trades, 7d window) | cluster-ORKA-1773778049710 |
Track record
40 reports on ORKA
7 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 10 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers